Mr. Richard Glickman reports

AURINIA ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING

The six incumbent directors of Aurinia Pharmaceuticals Inc. were elected at the company's annual general meeting held on June 21, 2017.

Detailed results of the vote by proxy for the election of directors are provided in the attached table.

            VOTING RESULTS FOR ELECTION OF DIRECTORS

Nominee                  Votes for (%)        Votes withheld (%)

Richard Glickman               96.70%                     3.30%
Benjamin Rovinski              99.09%                     0.91%
David Jayne                    71.78%                    28.22%
Hyuek Joon Lee                 98.95%                     1.05%
Lorin Randall                  75.43%                    24.57%
George Milne                   99.11%                     0.89%

Voting results on all matters voted on at the meeting will be filed on SEDAR and EDGAR.

About Aurinia Pharmaceuticals Inc.

Aurinia is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN. The company is headquartered in Victoria, B.C., and focuses its development efforts globally.

We seek Safe Harbor.